CA3180737A1 - Materials and methods for inhibiting a viral infection, including a coronavirus infection - Google Patents

Materials and methods for inhibiting a viral infection, including a coronavirus infection Download PDF

Info

Publication number
CA3180737A1
CA3180737A1 CA3180737A CA3180737A CA3180737A1 CA 3180737 A1 CA3180737 A1 CA 3180737A1 CA 3180737 A CA3180737 A CA 3180737A CA 3180737 A CA3180737 A CA 3180737A CA 3180737 A1 CA3180737 A1 CA 3180737A1
Authority
CA
Canada
Prior art keywords
biofilm
seq
virus
protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180737A
Other languages
English (en)
French (fr)
Inventor
Nicholas T. Monsul
Eva A. Berkes
Frederick T. BOEHM
Yu-Hsien Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quorum Innovations Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3180737A1 publication Critical patent/CA3180737A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3180737A 2020-06-06 2021-06-07 Materials and methods for inhibiting a viral infection, including a coronavirus infection Pending CA3180737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035733P 2020-06-06 2020-06-06
US63/035,733 2020-06-06
PCT/US2021/036104 WO2021248111A1 (en) 2020-06-06 2021-06-07 Materials and methods for inhibiting a viral infection, including a coronavirus infection

Publications (1)

Publication Number Publication Date
CA3180737A1 true CA3180737A1 (en) 2021-12-09

Family

ID=78831585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180737A Pending CA3180737A1 (en) 2020-06-06 2021-06-07 Materials and methods for inhibiting a viral infection, including a coronavirus infection

Country Status (11)

Country Link
US (2) US11826390B2 (https=)
EP (1) EP4161558A4 (https=)
JP (1) JP2023529152A (https=)
KR (1) KR20230025853A (https=)
CN (1) CN116133669A (https=)
AU (1) AU2021286002A1 (https=)
BR (1) BR112022024911A2 (https=)
CA (1) CA3180737A1 (https=)
IL (1) IL298401A (https=)
MX (1) MX2022015439A (https=)
WO (1) WO2021248111A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006163A (es) * 2019-11-26 2022-06-17 Quorum Innovations Llc Nuevas composiciones de barrera protectora y usos de las mismas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2007040446A1 (en) 2005-10-06 2007-04-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
BRPI0822997A2 (pt) * 2008-09-04 2015-06-23 Om Pharma Extratos imunomoduladores de bactérias lactobacillus e métodos para fabricação e uso dos mesmos
KR101378608B1 (ko) * 2011-04-13 2014-03-27 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
DK3324986T3 (da) * 2015-07-20 2022-01-31 Quorum Innovations Llc Materialer og fremgangsmåder til forbedring af immunreaktioner og hud- og/eller slimhindebarrierefunktion
CA3176797A1 (en) * 2020-05-06 2021-11-11 Nicholas T. Monsul Novel protein, and therapeutic and cosmetic uses thereof

Also Published As

Publication number Publication date
US20230136276A1 (en) 2023-05-04
AU2021286002A1 (en) 2023-01-19
JP2023529152A (ja) 2023-07-07
EP4161558A1 (en) 2023-04-12
BR112022024911A2 (pt) 2022-12-27
US20240075083A1 (en) 2024-03-07
KR20230025853A (ko) 2023-02-23
WO2021248111A1 (en) 2021-12-09
EP4161558A4 (en) 2024-06-19
IL298401A (en) 2023-01-01
CN116133669A (zh) 2023-05-16
MX2022015439A (es) 2023-03-22
WO2021248111A9 (en) 2022-12-22
US11826390B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
KR20130043625A (ko) 화합물들 및 그 용도
US12495800B2 (en) Protective barrier compositions, and uses thereof
US11649267B2 (en) Mitrecin A polypeptide with antimicrobial activity
US20240075083A1 (en) Materials and methods for inhibiting a viral infection, including a coronavirus infection
KR20180037185A (ko) 광범위의 항감염성 펩티드
US20250295748A1 (en) Treatment and prevention of viral infections
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
US20250025528A1 (en) Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials
KR102586836B1 (ko) 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR101765393B1 (ko) 탄저균 특이 용균 단백질 b4의 제조 방법 및 탄저균에 의해 유발되는 질환의 치료 방법
CN118632705A (zh) 用于预防或减少有机磷酸酯和其他有毒材料的毒性的材料和方法
KR20170052946A (ko) 탄저균 특이 용균 단백질 ap50-31의 제조 방법 및 탄저균에 의해 유발되는 질환의 치료 방법
KR102492395B1 (ko) 호랑나비 유충으로부터 유래된 펩타이드인 파필리오신-3 및 이의 용도
KR102430003B1 (ko) 아메리카왕거저리 유충으로부터 유래된 펩타이드인 조포바신-1 및 이의 용도
CA2649768A1 (en) Use of trap protein per se as an active ingredient for the manufacture of a medicament for the treatment of staphylococcus aureus infection
Shesha Characterizing the Cytotoxicity of Pseudomonas aeruginosa PAO1 on Triple Negative Breast Cancer Cells

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251124

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204